Q-omics provides the consensus-scored C11orf54 profile across patient tissues and cancer cell-line models. C11orf54 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C11orf54 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, C11orf54 RNA expression shows 21,167 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where C11orf54 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf54 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf54 survival associations across molecular data types. C11orf54 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf54 RNA expression–survival associations across cancer types. High C11orf54 expression shows unfavorable associations in ACC, but favorable associations in KIRC, KIRP, HNSC, MESO and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C11orf54 RNA expression.
This table summarizes C11orf54 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C11orf54. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf54 shows lower tumor expression in KICH, KIRP, THCA, COAD, LUSC and LUAD. The KICH box plot shows higher C11orf54 RNA expression in normal versus tumor tissue (log2 FC = −3.425, t-test p < 0.001).
This table shows molecular features associated with C11orf54 in patient tissues and cancer cell lines. In patient samples, C11orf54 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf54 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
